Arsenic diluted until nothing of it remains — a sugar pellet plus ritual. Open programs reported protection; where nobody knew who got what, fewer self-reported illnesses appeared but no difference in verified infection, and the supporting work came from the body promoting it. Harm — liver injury, one death — traces to product holding measurable arsenic, and to use instead of proven treatment. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Alanine aminotransferase | Under 20 U/L (men), under 17 U/L (women) | Earliest signal of liver-cell injury |
| Aspartate aminotransferase | Under 25 U/L | Confirms liver-cell injury; a ratio above 2 points elsewhere |
| Total bilirubin | 0.3–1.0 mg/dL | Impaired liver clearance; the jaundice threshold |
| Gamma-glutamyl transferase | Under 20 U/L | Bile-flow injury; the ethanol carrier in liquid potencies |
| Whole-blood arsenic | Under 5 µg/L | Recent intake from low-potency or contaminated product |
| Urinary speciated inorganic arsenic | Under 10 µg/L, or under 15 µg/g creatinine | The only test separating toxic inorganic arsenic from seafood forms |
| Platelet count | 200–300 × 10⁹/L | A falling count signals advancing liver disease |
| Estimated glomerular filtration rate | Above 90 mL/min/1.73 m² | The kidney is a target organ for arsenic and heavy metals |
| Symptom profile score | No established target; the change from the individual's own recorded baseline | Captures the outcome the preparation is taken for |
Cadence: Baseline draw before starting. For a one-week to one-month course, liver panel at 4 weeks. For continued use, liver enzymes and urinary speciated arsenic at 4 weeks, 3 months, then every 6 to 12 months, and at once on any warning symptom.